Clinical Trial Detail

NCT ID NCT04201145
Title Pembrolizumab + Defactinib In Pleural Mesothelioma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Raphael Bueno, MD
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Defactinib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.